New hope for rare kidney disease patients: early access to pegcetacoplan
NCT ID NCT04729062
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a potential treatment option before full approval.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegcetacoplan
- What this could lead to
- If successful, this could offer a treatment option for patients with rare kidney diseases who have limited alternatives.
- What could go wrong
- This is an early access program, not a full trial, so results may not confirm long-term safety or effectiveness. The drug may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for C3 GLOMERULONEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted therapy tame rare kidney diseases in daily practice?
- Can a gene-silencing drug calm overactive complement in kidney disease?
- New drug iptacopan studied for rare kidney disease C3G
- New drug aims to stop kidney disease from coming back after transplant
- New drug combo aims to tame rare kidney diseases
- New hope for rare kidney disease: experimental drug NM8074 enters human trials